Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"MXAMDUD Thursday, 02/13/20 11:57:33 AM
Re: None 0
Post #
281780
of 281848
I have been told by a friend that treatment for his colonic disease requires a 4 hour clinic visit with an IV and the EOB report indicates about $1K for the treatment every 8 weeks or so. He indicates that taking a pill with so many side effects would be of limited benefit for many This seems like the type of news that would have BPs indifferent to get involved with the B franchise considering the limited market. I hear some of the ongoing backroom discussions and especially LW is disappointed in today's results."
Where did "your friend" hear of "so many side effects"? Why don't you invite "your friend" to post his concerns himself here on the board?
Where did you "hear" about the "backroom discussions"?
[Does the AVXL koolaid have a leak?/b]
Don't know about today but a few months back the leak said down to $2.20.
Even if it hits a 100 share buy isn't going to move it.
red on the day as predicted. bearish hammer
You mean like yesterday when it closed up 4.29% green on "heaving selling", then today closed up 4.89% on a "bearish hammer",lol?
Wow, all that heavy selling caused it to rise 4.29%,lol.
Is it possible to see the light at end of tunnel this year for PXYN?
AVXL>>> Very promising news from Australia
A drug which appears to slow Alzheimer's is being offered to more Victorians as part of a clinical trial. @EmilyRice28 #9News pic.twitter.com/IqKUXKzlhA
— 9News Melbourne (@9NewsMelb) January 28, 2020
VERY PROMISING ALZHEIMERS NEWS FROM AUSTRALIA
A drug which appears to slow Alzheimer's is being offered to more Victorians as part of a clinical trial. @EmilyRice28 #9News pic.twitter.com/IqKUXKzlhA
— 9News Melbourne (@9NewsMelb) January 28, 2020
I have been patiently (sometimes very impatiently) waiting here since 1987. Is there a possibility I (we) have finally seen a light at the end of the tunnel ?
NNVC up 270% at 2:40 pm Nanoviricides shares are trading higher following an outbreak of the Wuhan coronavirus in China, which has now reportedly spread to the US. The company operates in the viral diseases space.
Jan 21, 2020 1:39p ETBenzinga Stock Analysis
NNVC NOW UP PLUS 270% at 2;40 pm.
Nanoviricides shares are trading higher following an outbreak of the Wuhan coronavirus in China, which has now reportedly spread to the US. The company operates in the viral diseases space.
Jan 21, 2020 1:39p ETBenzinga Stock Analysis
NNVC exploding up today +190%
IPIX up 14% again today with an extension of yesterday's news--Innovation Pharmaceuticals Announces Dose Escalation
8:30 am ET January 17, 2020 (Globe Newswire) Print
Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage pharmaceutical company, announced today that the Company has received agreement from the study's Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
Safety findings from the first cohort were reviewed by the DEC. The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration to a second cohort per trial design. Dosing of the second cohort is scheduled for Tuesday, January 21, 2020.
Dosing of the third and final cohort is anticipated to be completed by the end of January, with topline data to follow shortly thereafter.
In this Phase 1 clinical trial, nine subjects will be enrolled in the single-center, randomized, single-blinded, placebo-controlled, single dose-escalation trial, three subjects per cohort. In each cohort, two subjects will receive Brilacidin (cohort 1: 50mg; cohort 2: 100mg; and cohort 3: 200mg) and one subject will receive placebo. Assessments will include the safety, toleration, and pharmacokinetics of oral Brilacidin, and whether the drug is being dispersed directly in the colon through the use of delayed release tablets, as assessed by gamma scintigraphy.
About Brilacidin for IBD
Inflammatory Bowel Disease (IBD) is a hard-to-treat, chronic, autoimmune condition that affects approximately 10 million people worldwide, including 3 million people in the U.S., with 70,000 newly diagnosed cases each year. The overall GI market sector is estimated to grow from $35.7 billion in 2015 to $48.4 billion by 2022. Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation plans including oral tablets for Ulcerative Colitis and Crohn's Disease, and enema, foam and/or gel for mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS. In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug's efficacy. In late 2018, the Company presented a scientific poster--Brilacidin for Inflammatory Bowel Disease (available for download here, pdf)--at the inaugural "IBD Innovate 2018" conference, hosted by the Crohn's & Colitis Foundation. Brilacidin may be particularly beneficial in treating IBD due to: 1) its ability to inhibit Phosphodiesterase 4 (PDE4), which is being pursued as a novel therapeutic avenue in IBD; and 2) its potential to compensate for defensin deficiencies that are implicated in the pathogenesis of IBD.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals In
IPIX up again today on an extension of yesterday's news --Innovation Pharmaceuticals Announces Dose Escalation
8:30 am ET January 17, 2020 (Globe Newswire) Print
Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage pharmaceutical company, announced today that the Company has received agreement from the study's Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
Safety findings from the first cohort were reviewed by the DEC. The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration to a second cohort per trial design. Dosing of the second cohort is scheduled for Tuesday, January 21, 2020.
Dosing of the third and final cohort is anticipated to be completed by the end of January, with topline data to follow shortly thereafter.
In this Phase 1 clinical trial, nine subjects will be enrolled in the single-center, randomized, single-blinded, placebo-controlled, single dose-escalation trial, three subjects per cohort. In each cohort, two subjects will receive Brilacidin (cohort 1: 50mg; cohort 2: 100mg; and cohort 3: 200mg) and one subject will receive placebo. Assessments will include the safety, toleration, and pharmacokinetics of oral Brilacidin, and whether the drug is being dispersed directly in the colon through the use of delayed release tablets, as assessed by gamma scintigraphy.
About Brilacidin for IBD
Inflammatory Bowel Disease (IBD) is a hard-to-treat, chronic, autoimmune condition that affects approximately 10 million people worldwide, including 3 million people in the U.S., with 70,000 newly diagnosed cases each year. The overall GI market sector is estimated to grow from $35.7 billion in 2015 to $48.4 billion by 2022. Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation plans including oral tablets for Ulcerative Colitis and Crohn's Disease, and enema, foam and/or gel for mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS. In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug's efficacy. In late 2018, the Company presented a scientific poster--Brilacidin for Inflammatory Bowel Disease (available for download here, pdf)--at the inaugural "IBD Innovate 2018" conference, hosted by the Crohn's & Colitis Foundation. Brilacidin may be particularly beneficial in treating IBD due to: 1) its ability to inhibit Phosphodiesterase 4 (PDE4), which is being pursued as a novel therapeutic avenue in IBD; and 2) its potential to compensate for defensin deficiencies that are implicated in the pathogenesis of IBD.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals In
IPIX up 21% on news todayInnovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020
12:00 pm ET January 16, 2020 (Globe Newswire) Print
Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage pharmaceutical company, is pleased to inform shareholders that the Company has dosed the first cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers. This study formally launches the Company's clinical program in Ulcerative Colitis.
Assessments will include the safety, toleration, and pharmacokinetics of oral Brilacidin, and whether the drug is being dispersed directly in the colon, as assessed by gamma scintigraphy. Dosing of all cohorts in the Phase 1 trial is expected to be completed within several weeks, and topline data to follow shortly.
The start of this Phase 1 trial is a major milestone for the Company, a key part of its broader clinical program in Inflammatory Bowel Diseases (IBD). The study's primary objective is to show that Brilacidin can be delivered orally and selectively to the colon. This will enable the Company to treat more extensive forms of GI disease, primarily Ulcerative Colitis and Crohn's Disease.
Notably, in other clinical trials, Brilacidin has been shown to be a promising drug candidate in multiple therapeutic areas and across various modes of administration. In a previous Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring). Evidence of mucosal healing was supported based on endoscopic review, an increasingly important measure toward establishing a drug's efficacy. These trial results led to the licensing of Brilacidin for UP/UPS to a global pharmaceutical company.
If later trial results in the Ulcerative Colitis program are similarly as successful to those achieved in the completed UP/UPS study, the Company believes oral Brilacidin's therapeutic potential and licensing opportunities will be significant. Big Pharma is willing to pay a premium for novel oral clinical assets in development for IBD, based on strong patient preference for easily-administered oral drugs and other economic advantages of oral delivery compared to costly and burdensome IBD treatments delivered via injection and IV infusion.
In this clinical trial, nine subjects will be enrolled in the single-center, randomized, single-blinded, placebo-controlled, single dose-escalation trial, three subjects per cohort. In each cohort, two subjects will receive Brilacidin (cohort 1: 50mg; cohort 2: 100mg; and cohort 3: 200mg) and one subject will receive placebo.
The Company will keep shareholders updated as it works to complete this short Phase 1 trial.
About Brilacidin for IBD
Inflammatory Bowel Disease (IBD) is a hard-to-treat, chronic, autoimmune condition that affects approximately 10 million people worldwide, including 3 million people in the U.S., with 70,000 newly diagnosed cases each year. The overall GI market sector is estimated to grow from $35.7 billion in 2015 to $48.4 billion by 2022. Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation plans including oral tablets for Ulcerative Colitis and Crohn's Disease, and enema, foam and/or gel for mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS. In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug's efficacy. In late 2018, the Company presented a scientific poster--Brilacidin for Inflammatory Bowel Disease (available for download here, pdf)--at the inaugural "IBD Innovate 2018" conference, hosted by the Crohn's & Colitis Foundation. Brilacidin may be particularly beneficial in treating IBD due to: 1) its ability to inhibit Phosphodiesterase 4 (PDE4), which is being pursued as a novel therapeutic avenue in IBD; and 2) its potential to compensate for defensin deficiencies that are implicated in the pathogenesis of IBD.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020
12:00 pm ET January 16, 2020 (Globe Newswire) Print
Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage pharmaceutical company, is pleased to inform shareholders that the Company has dosed the first cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers. This study formally launches the Company's clinical program in Ulcerative Colitis.
Assessments will include the safety, toleration, and pharmacokinetics of oral Brilacidin, and whether the drug is being dispersed directly in the colon, as assessed by gamma scintigraphy. Dosing of all cohorts in the Phase 1 trial is expected to be completed within several weeks, and topline data to follow shortly.
The start of this Phase 1 trial is a major milestone for the Company, a key part of its broader clinical program in Inflammatory Bowel Diseases (IBD). The study's primary objective is to show that Brilacidin can be delivered orally and selectively to the colon. This will enable the Company to treat more extensive forms of GI disease, primarily Ulcerative Colitis and Crohn's Disease.
Notably, in other clinical trials, Brilacidin has been shown to be a promising drug candidate in multiple therapeutic areas and across various modes of administration. In a previous Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring). Evidence of mucosal healing was supported based on endoscopic review, an increasingly important measure toward establishing a drug's efficacy. These trial results led to the licensing of Brilacidin for UP/UPS to a global pharmaceutical company.
If later trial results in the Ulcerative Colitis program are similarly as successful to those achieved in the completed UP/UPS study, the Company believes oral Brilacidin's therapeutic potential and licensing opportunities will be significant. Big Pharma is willing to pay a premium for novel oral clinical assets in development for IBD, based on strong patient preference for easily-administered oral drugs and other economic advantages of oral delivery compared to costly and burdensome IBD treatments delivered via injection and IV infusion.
In this clinical trial, nine subjects will be enrolled in the single-center, randomized, single-blinded, placebo-controlled, single dose-escalation trial, three subjects per cohort. In each cohort, two subjects will receive Brilacidin (cohort 1: 50mg; cohort 2: 100mg; and cohort 3: 200mg) and one subject will receive placebo.
The Company will keep shareholders updated as it works to complete this short Phase 1 trial.
About Brilacidin for IBD
Inflammatory Bowel Disease (IBD) is a hard-to-treat, chronic, autoimmune condition that affects approximately 10 million people worldwide, including 3 million people in the U.S., with 70,000 newly diagnosed cases each year. The overall GI market sector is estimated to grow from $35.7 billion in 2015 to $48.4 billion by 2022. Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation plans including oral tablets for Ulcerative Colitis and Crohn's Disease, and enema, foam and/or gel for mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. As released previously, a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS. In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug's efficacy. In late 2018, the Company presented a scientific poster--Brilacidin for Inflammatory Bowel Disease (available for download here, pdf)--at the inaugural "IBD Innovate 2018" conference, hosted by the Crohn's & Colitis Foundation. Brilacidin may be particularly beneficial in treating IBD due to: 1) its ability to inhibit Phosphodiesterase 4 (PDE4), which is being pursued as a novel therapeutic avenue in IBD; and 2) its potential to compensate for defensin deficiencies that are implicated in the pathogenesis of IBD.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
It wasn't easy to hang in there for 33 years. I bought and sold a few times but believed in the science and the public need as one of my best friends died a horrible death with H&N Ca in his mid 50's.
I also knew that the average time for a new drug to reach the market is 10-12 years from discovery to FDA approval and sale. Clinical trials 6-7 years and average cost 2-3 BILLION. That is why I have a low tolerance for those complaining about a young drug like AVXL not being on the market today.
It's a sad situation in "modern" medicine when a clerk at a hospital or insurance company dictates the emergency treatment of a patient:
wasadiver Member Level Friday, 12/27/19 11:20:48 PM
Re: skitahoe post# 257246 0
Post #
257248
of 257820
A few years ago I had a patient brought into my Level I Trauma Center by EMS, shot 19 times in the pelvis. The patient was alive but was going to die quickly if we didn’t act immediately. I called out to the Unit Secretary to get us 2 units of uncrossed blood immediately. Before the Electronic Medical Record we’d shout out an order in the thick of such traumas and what ever we needed showed up almost immediately. But as we worked to place IV lines, check the pelvis with a bedside ultrasound, and pour in fluids as the OR got ready I waited and waited for the blood to arrive. It previously would have taken literally 1 minute. It was now 10 minutes, critical time in a life and death gunshot victim. I asked the secretary what was going on and she told me they needed the proper order in the computer or they couldn’t release the blood. I immediately ran the 100 or so yards down the hall to the blood bank and confronted the tech, who was standing there with the cooler of packed red blood cells. I yelled to him to give me the blood. He responded that he couldn’t release it until the right order was put in or he might lose his job. I told him to put the cooler on the floor and I would take it, otherwise I was going to take it from him violently if necessary. He was horrified to even be in this situation but it was surreal; I had a dying patient that needed this blood NOW, and he was afraid of losing his job because some manager beat it into his head that he’d be in big trouble if he didn’t follow their rules (so they could track the money of course).
This is just the tip of the iceberg about how medicine has become so corporate that a person’s life could be lost due to stupid bureaucracy brought about in the name of “efficiency” but is really about how to maximize profit at the expense of real time person to person interactions that are essential to the practice of medicine. It’s worse than anyone outside of being a Physician, Nurse, Medical Technician, or any other provider of care could possibly imagine. I spend more time at my computer, and I have a scribe who does my notes, ordering labs, imaging, and medications, than I do with my patients. I have to push myself to get up and go re-check them and interact. It actually takes discipline to do this, something so absurd I couldn’t have ever imagined it when I was in training.
Foosfund-BIR was the first stock newsletter I subscribed to in the mid-1980s. I was working for a major pharmaceutical company with a nice 401K plan but decided to develop a small "Vegas" portfolio with perhaps 1% of my salary. I bought my first BIR rec in 1987-CVM (Cel-Sci) developing an immunotherapeutic agent as a first-line drug for head and neck cancer (pre chem-rad). That drug is now nearing the end of its Phase III trial waiting for 298 events (deaths) to occur before ending.
CVM is the example I refer to when investors complain about AVXL (or other developing biotechs) being too slow for finals. After 33 years the company is excited about seeing a positive end in 2020. I've also said at least 80% should not invest in biotechs as they often look at biotech as just another "widget"-planned this week, produced next week, and sold the week thereafter.
I am retired and my income is my IRA funds but my "play money" consists of 10 "gambling" stocks of which AVXL is one of my top two with much promise IMO.
Yes, I also purchased AVXL recommended by BIR a few years back.
Three years old???
Is it still worth $15 BILLION ?
no doubt seasonal factors
are attracting
smart money.
time to buy.
Looks like smart buyers are taking your smart advice-up almost .20 today.
Thanks. I actually googled it and went into settings and eliminated whatever it was. Also reported the low-life scammers to the FTC.
Any help here will be appreciated. The following scam shows up only on my iPad and on the IHub site. While on investorshub a popup scam "you have been picked for a $1000 prize" website luckyguys.top/prize/luckyus-ad hijacks my iPad screen. Trying to leave that site is impossible and another scam site 7year.co appears. I have to completely leave IHub then when I return the same scam appears. My PC doesn't have this problem perhaps because it runs on Windows 10 and I have Avast antivirus. Can I fix this by getting Avast or another antivirus on iPad?
How can I get these criminal scammers arrested? Thanks much.
Wow, perhaps a TRIFECTA of news???
Yes, those who studied and passed Business 101 will be buying, buying, buying,
Wow, a swarm of illegal market manipulators have arrived and duly reported to the SEC.
Interesting post from another board regarding possibilities for this PENNY STOCK for those who understand biotech startups:
Bob
When I heard that AVXL had been awarded a PRV certificate for their work in Retts, I had my son do some research on PRVs. He works for a VC fund. I would think that the info my son (PhD Immunology/Dartmouth) dug up might be a tad startling to many. I wanted to share it with the group should you not be aware of it.
In summary, there have only been 34 PRV's issued since 2006, primarily for either rare tropical or pediatric diseases. Pediatric PRVs can be transferred an unlimited number of times. A firm that makes use of the PRV for a FDA drug review will have to cough up approx. $2mil to exercise it. My son said the PRV only knocks off about 4 months in the drug review process with the FDA.
Now for the knock your socks off bit of info... hang onto your seat. The average price of the 14 PRVs which were sold to another drug firm averaged $141,776,923.00 in price. AMAZING! Bottom line... AVXL has been awarded with a somewhat liquid asset worth in excess of $100mil. The lowest price on record was for $67mil. The highest was for $350mil. The avg price of two PRVs sold in 2019, where the price became public, averaged $100mil.
I believe AVXL has approx. 50mil shares outstanding. Divide that into a new found asset worth $100mil and you get a potential $2 worth added to share value literally overnight.
I just arrived back from a trip. PLEASE FILL US IN ON THE GREAT NEWS EXPECTED FROM THIS PAST WEEKThanks.
More illegal manipulation.
Correct, and a little knowledge of Finance 101,lol.
Kmadd Friday, 11/08/19 05:39:34 PM
Re: rayovacAAA post# 218257 0
Post #
218260
of 218324
Just Google bankruptcy, debt and what it means to issue and own shares and you'll realize how silly your statements are.
And btw Anavex has earnings in the form of grant money.
It helps to have just a little knowledge.
Reality SUX with pennystocks when many of the general public out there are too misinformed to understand that Merck, Eli Lilly, Bayer, Novartis, etc; etc; were once penny stocks,lol
Also, don't forget that clowns are put in a circus for comedy and making people laugh.
Hmmm, if I remember correctly the FDA awarded Kevetrin Orphan Drug designation. If so, could the FDA be off base?
CVM---SHOULD HAVE ACTED ON MY PREVIOUS POST. CEO BOUGHT 3725 more shares in high $6's-now trading at $7.20.
AVXL Alzheimer's drug up again today.
Exactly. And the SOS, childish, 24/7.
NEW HOPE FOR ALZHEIMERS/CNS CURE
AVXL CONSENSUS BUY RATING $9.33-PPS NOW $2.70s. Great time to buy.https://mayfieldrecorder.com/2019/10/24/anavex-life-sciences-nasdaqavxl-upgraded-by-zacks-investment-research-to-buy.html
CVM= GREAT BUY THIS MORNING!!!Why? Great stockholder letter yesterday stating # expected events (deaths) not reached yet (expected months ago) meaning more trial patients likely living longer. Then perpetual liar and distorter Fartstein puts out hit piece. PPS tumbles then recovering. Recently hit over $9. Buy in 6's today!